IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx(TM) (SVDx) test, formerly known as the PULS(TM) Cardiac Test, is now more accessible than ever for patients in the northeastern United […]

SmartVascular Dx(TM) Test Elevates Vascular Risk Detection in the Northeast & Partnership with MOMS GlobeNewswire August 01, 2025 IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx(TM) (SVDx) test, formerly

(CNSX:IDK),(OTC US:IDKFF),(Other OTC:IDKFF),(CNSX:IDK.CN), TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce that it has closed its previously announced private placement financing (the “Private

ThreeD Capital Inc. Completes Private Placement Financing GlobeNewswire August 01, 2025 TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce that it has closed

abrdn Income Credit Strategies Fund (NYSE: ACP) (the “Fund”), a closed-end fund, has announced that it filed with the U.S. Securities and Exchange Commission (“SEC”) on August 1, 2025, a prospectus supplement to its registration statement under which it may offer and sell from time to time, in one or more at-the-market offerings, the Fund's

(NYSE:AVK),(NYSE:GBAB),(NYSE:GOF),(NYSE:GUG), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution schedule for each closed-end fund (collectively, the “Funds” and each, a “Fund”). The following dates apply to the distributions: Record Date August 15, 2025 Ex-Dividend Date August 15,

Guggenheim Investments Announces August 2025 Closed-End Fund Distributions GlobeNewswire August 01, 2025 NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution schedule for each closed-end fund (collectively, the “Funds” and each, a “Fund”). The following dates apply to

(NASDAQ:ANIK), NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK). The investigation concerns whether Anika and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT

Kirby McInerney LLP Announces Investigation Against Anika Therapeutics, Inc. (ANIK) on Behalf of Investors GlobeNewswire August 01, 2025 NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) — The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK). The investigation concerns whether Anika and/or certain of its

WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the